Practical insights on deal-making covering licensing, partnering and M&A in the pharmaceutical, biotechnology, diagnostics and medical devices sector -get acquainted with state-of-the-art concepts and practices.
Introduction The biopharmaceutical industry landscape is constantly evolving, and in-licensing and partnering deals are vital corporate strategies for driving innovation, devising new products, and gaining a competitive edge in the…
Criteria and Strategies for Choosing the Right Comparable Companies in Biotech Valuation When valuing a private or public biotech company using market multiples, one of the most critical first steps…
Proven Strategies to Speed Up Biotech and Pharma Partnering & Out-Licensing Deals Are you frustrated with the slow and time-consuming process of out-licensing biopharma assets? The good news is that…
How to Expedite Biotech Partnering & Out-Licensing Deals by Looking Beyond Traditional Prospects Partnering and out-licensing are central to the growth of life sciences companies, especially for emerging pharmaceutical and…
How to Leverage Competitive Intelligence for Smarter In-Licensing Deals for Pharma Business Development and Corporate Development Pharma Business Development and Licensing (BD&L) activities covering pharmaceutical licensing and partnering are integral…
How to Determine Accurate Addressable Market Size in Life Sciences Commercial Due Diligence Market size is one of the critical elements in the life sciences commercial due diligence, new product…
How to Conduct Robust Commercial Due Diligence by Looking Beyond Generics in Pharma Businesses Investors need to look beyond generics in the pharmaceutical commercial due diligence (CDD) for investment in…
How to Accurately Assess the True Addressable Market in Healthcare and Life Sciences Due Diligence Determining the appropriate addressable market is often one of the critical success factors in commercial…
How to Address Terminal Value Challenges in Pharmaceutical Asset Valuation Several stakeholders who have an interest in pharmaceutical assets employ a multitude of methods to conduct valuations. Among various valuation…